Nov 12, 2024 7:30 am EST Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
Nov 4, 2024 7:30 am EST Abeona Therapeutics® Announces Participation in November Investor Conferences
Nov 1, 2024 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 29, 2024 7:30 am EDT Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
Oct 1, 2024 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 3, 2024 7:30 am EDT Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Sep 2, 2024 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 14, 2024 7:30 am EDT Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
Aug 13, 2024 7:30 am EDT Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
Aug 12, 2024 7:30 am EDT Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
